Alpha Tau Medical Ltd (DRTS) Stock Score, Valuation & Financial Research

Alpha Tau Medical Ltd is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for DRTS

Alpha Tau Medical Ltd does not currently have a complete Wall Street Score. The stored market price is USD 14.77. These figures are a research snapshot, not a buy or sell recommendation.

What Alpha Tau Medical Ltd does

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company is headquartered in Jerusalem, Israel.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Alpha Tau Medical is a clinical-stage oncology therapeutics company that does not currently generate revenue from product sales. Its business model focuses on the research, development, and potential future commercialization of its proprietary Alpha DaRT technology for treating solid tumors, relying on capital raises and financing activities to fund its ongoing clinical trials and operations.

Products and services

  • The company's primary product candidate is Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy), a medical device technology that delivers alpha-particle radiation directly into solid tumors to damage and kill cancer cells.

Brands and product families

  • Alpha DaRT — The company's core proprietary radiation therapy technology platform. Source

Customer types

Academic cancer centers; Clinical trial sites.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company relies on third-party contract manufacturers for the production of its medical devices and components; specific supplier names are not disclosed. Source

Business relationships and partnerships

  • Tel Aviv University — The company maintains a relationship with Tel Aviv University, where the Alpha DaRT technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari. Source

Business strengths to evaluate

  • Proprietary Alpha DaRT technology platform Source

Business risks and research considerations

  • History of operating losses and lack of revenue Source
  • Significant regulatory and clinical trial execution risks Source

Sources: Company research source · Tel Aviv University · Significant regulatory and clinical trial execution risks

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

DRTS financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 14.77
Market capitalization:
1.33B (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -92.57M
Free cash flow:
USD -32.76M
Cash:
USD 22.99M
Total debt:
USD 15.15M
EPS:
USD -1.04

What stands out

  • Free cash flow is USD -32.76M, negative for the stored period.
  • The balance sheet shows USD 22.99M of cash versus USD 15.15M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a missing revenue history warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 7.84M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for DRTS

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can DRTS fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is DRTS likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for DRTS to reach sustainable profitability?
  • What does the current missing revenue history warning mean for the reliability or interpretation of DRTS's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research DRTS

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.